00:00We have widespread and capillary access throughout the country thanks to the presence of departments
00:10and oncology divisions that deal specifically with the treatment of the mammary tumor.
00:16We have the opportunity to discuss in multidisciplinary groups not only the opportunities that the
00:23new drugs guarantee to our patients, but above all the innovation in the paths that are guaranteed
00:30to our patients through the innovation of what are the aspects of recognition of specific
00:37risk characteristics, the possibility of identifying new molecular targets, all in an extremely
00:44harmonious and aggregated set that allows us, gives us a very important operational advantage.
00:52The timing of the therapies, therefore the ability of a real takeover of patients to make
00:59available innovative treatments, is based on equally innovative paths.
01:04Paths that are discussed in our country in an extremely widespread and capillary way,
01:10thanks to the presence of the units that treat and manage patients with the mammary tumor.
01:16And that's why there is an extraordinary opportunity for innovation.
01:21It is a capacity that concerns not only the identification of new molecular targets or the
01:28research of new pharmacological therapies, but above all the ability to better listen to patients,
01:34what are those side effects that to the doctor seem apparently low-level, low-profile,
01:42low-impact, but that instead lived by patients no longer for a few months, but for years,
01:48can represent a really serious link.
01:51That is why innovation must pass not only through the availability of new drugs,
01:57but above all through a renewal of the diagnostic-therapeutic paths capable of guaranteeing
02:04that timing that is fundamental in this phase of the disease.
Comments